Organogenesis Q4 revenue down 10% YoY; FY2023 guidance flat to +2%

Organogenesis Holdings Inc.

2022-FY EPS reported $0.12 revenue$450,893,000

Q4 2022 net revenue $115.5M (-10% YoY); net income $7.5M vs $51.0M in Q4 2021.
FY2022 net revenue $450.9M (-4% YoY); net income $15.5M vs $94.2M in FY2021.
FY2023 guidance: revenue $450-462M (flat to +2%); net income $7.2-13.9M.
PuraPly revenue expected to decline 18-26% in FY2023 to $180-200M.
Adjusted EBITDA FY2023 guidance $36.5-46.0M vs $49.3M in FY2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Organogenesis Holdings Inc. reported the fourth quarter ended December 31, 2022 results: revenue $115.5 million, net income $7.5 million, EPS $0.06 per share. Guidance initiated.

Period: the fourth quarter ended December 31, 2022
Revenue: $115.5 million
Net income: $7.5 million
EPS: $0.06 per share
Guidance: initiated
Result: reported results

Exact text from the filing

Medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2022. Fourth Quarter 2022 Financial Results Summary: • Net revenue of $115.5 million for the fourth quarter of 2022, a decrease of 10% compared to net revenue of $127.9 million for the fourth quarter of 2021. Net revenue for the fourth quarter of 2022 consists

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Organogenesis Holdings Inc. reported the year ended December 31, 2022 results: revenue $450.9 million, net income $15.5 million. Guidance initiated.

Period: the year ended December 31, 2022
Revenue: $450.9 million
Net income: $15.5 million
Guidance: initiated
Result: reported results

Exact text from the filing

of 2022, compared to Adjusted EBITDA of $26.3 million for the fourth quarter of 2021, a decrease of $12.3 million. Fiscal Year 2022 Financial Results Summary: • Net revenue of $450.9 million for the year ended December 31, 2022, a decrease of 4% compared to net revenue of $467.4 million for the year ended December 31, 2021. Net revenue for the year ended December 31,

View on SEC.gov

Browse all earnings releases →

Organogenesis Holdings Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-005554

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.